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Abstract: In patients suffering from oral cavity cancer surgical treatment is complex 
because it is necessary to remove carcinoma and lymph node metastasis (through a radical 
unilateral or bilateral neck dissection) and to reconstruct the affected area by means of free 
flaps. The saliva stagnation in the post-operative period is a risk factor with regard to local 
complications. Minor complications related to saliva stagnation (such as tissue maceration 
and wound dehiscence) could become major complications compromising the surgery or 
the reconstructive outcome. In fact the formation of oro-cutaneous fistula may cause 
infection, failure of the free flap, or the patient’s death with carotid blow-out syndrome. 
Botulinum injections in the major salivary glands, four days before surgery, temporarily 
reduces salivation during the healing stage and thus could reduce the incidence of  
saliva-related complications. Forty three patients with oral cancer were treated with 
botulinum toxin A. The saliva quantitative measurement and the sialoscintigraphy were 
performed before and after infiltrations of botulinum toxin in the major salivary glands. In 
all cases there was a considerable, but temporary, reduction of salivary secretion. A lower 
rate of local complications was observed in the post-operative period. The salivary 
production returned to normal within two months, with minimal side effects and 
discomfort for the patients. The temporary inhibition of salivary secretion in the  
post-operative period could enable a reduction in saliva-related local complications, in the 
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incidence of oro-cutaneous fistulas, and improve the outcome of the surgery as well as the 
quality of residual life in these patients.  
Keywords: Botulinum toxin; salivary production; oral cancer; free flap complications; 
saliva-related complications; forearm free flap; oro-cutaneous fistula; salivary  
major glands  
 
1. Introduction 
In the majority of patients with oral cancer. Tumor excision and neck dissection must be followed 
by microsurgical reconstruction of the affected area. This radical surgical treatment associated with 
chemotherapy and radiotherapy improves the prognosis and the life expectancy of these often very 
young patients. For this reason the microsurgical reconstruction is really important and has to be safe 
and effective, in order to improve the quality of life of these unfortunate patients. Despite careful 
postoperative monitoring, systemic antibiotic therapy and careful nutrition, the incidence of local 
complications after these operations, is high. The percentage of wound dehiscence, infection and 
fistula formation in some reports is very high (up to 40%) [1–3]. 
In a small percentage of cases, complications can appear due to technical errors and incorrect 
surgical planning (for example an inappropriate choice of flap), but in most cases the main reason for 
local complications is saliva stagnation, caused by reduced clearance ability of the mouth, reduced 
capacity to swallow, and increased salivary secretion. In fact the saliva causes tissue maceration, 
wound dehiscence and bacterial contamination, which may often cause, on day five or six after the 
surgery, the formation of a dangerous oro-cutaneous fistula, that compromise the reconstruction and, 
sometimes, the life of the patient (carotid artery blowout syndrome).  
Infiltration of botulinum toxin in the major salivary glands was used for the first time (Bushara) in 
patients suffering from amyotrophic lateral sclerosis and other neurological disorders caused by 
muscarinic type cholinergic hyperactivity [4–10]. 
The authors, who had experience with botulinum toxin A (BTXA) for the aesthetic treatment of 
wrinkles, thought that infiltration of botulinum toxin A in the major salivary glands, in patients who 
require reconstructive microsurgery of the oral cavity by means of free flaps, could temporarily 
decrease salivary production up to 70% and then reduce of the incidence of local complications caused 
by the stagnation of saliva [11]. 
2. Results and Discussion 
From January 2004 to June 2012, 43 patients suffering from oral cavity carcinoma underwent 
surgery; there are three phases of surgery: tumor excision, neck dissection (unilateral or bilateral) and 
microsurgical reconstruction with free flaps.  
Carcinoma was located in the tongue in 18 cases and in the floor of the mouth in 13 cases; it was 
disseminated widely in both locations in 12 cases. After wide radical surgery (excision of the area 
affected by the cancer and neck dissection) microsurgical reconstruction always followed.  
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Different kinds of flaps were prepared: 14 ALT flaps, 16 forearm flaps, nine chimeric ALT-vastus 
lateralis, a double microsurgical free flap of rectus abdominis and a fibula flap in three cases. 
All the patients, underwent sialoscintigraphy and a quantitative measurement of salivary secretion 
at the pre-operative period (Figure 1 left).  
Figure 1. Left, pre-operative sialoscintigraphy; Right, sialography 15 days after btx injections. 
 
The measurement of the salivary secretion was performed by setting four rollers of gauze 
(previously weighed using precision scales) for 2 min in the patient’s gingival fornix. After  
2 min, every roller was weighed and the salivary secretion was quantified.  
Sialography before the surgery was normal in almost all patients and saliva production was higher 
than normal in just a few cases.  
The infiltration technique is easy to perform. Four days before the surgery the authors injected the 
salivary glands with BTX (Figure 2). 
First 100 U of BTX A (Botox, Allergan) was diluted in 1 cc of NaCl (0.9%).  
Then a 1 mL syringe with a 29 gauge needle was used. The major salivary glands were marked for 
the injection. All patients gave informed consent for this procedure.  
The superficial and deep lobes of the parotid gland were marked and injected; 3–4 injections 
per lobe.  
The injection points for the deep lobe are in a 3 cm-diameter-area located between the mastoid 
process and the mandibular ascending ramus (total of 15–20 U of toxin); three injections for the 
superficial lobe in a 3 cm-diameter-area located 1 cm under and in front of the tragus and on the back 
edge of the masseter muscle (15–20 U). Ten units of toxin were infiltrated for the submandibular 
glands (Figure 2). Of course, infiltration of the gland ipsilateral to the dissection of the neck is not 
necessary, since the gland is to be removed during surgery 
Toxins 2012, 4 959 
 
 
Figure 2. Sites of botox injections. 
 
The injections of the submandibular glands are not really important because in the majority of cases 
these glands are to be removed during the neck dissection. The total quantity of the infiltrated toxin 
was 80–100 U for each patient [8]. 
The greatest effect of the toxin was noticed between the fifth and eighth day after the injections 
(between the first and fourth days after surgery).  
The quantitative measurement of saliva was performed three and eight days after the infiltration 
using the method with gauze rollers in the gingival fornix. This method showed a 50% reduction of 
secretion on the third day after the injection and a 70% reduction on the eighth day (four days 
after surgery). 
In 2010 the authors published the results of this evaluation on a smaller sample of patients  
(20 patients), and showed that while the mean salivation before BTX infiltrations was 0.24 gr/2 min, 
the mean salivation eight days after BTX injections was 0.08 gr/2 min.  
The data are statistically significant and prove that BTX injection temporarily reduces the saliva 
production (student’s t test 4; p > 3,883; α < 0,001; gdl 19) [11]. 
Sialoscintigraphy with Tc 99, repeated 15 days after the toxin infiltration (Figure 1, right) showed a 
90% reduction of the function of the parotid and submandibular glands (clearly in patients in which the 
submandibular glands were not excised during the surgical operation), with a total of 80% reduction of 
salivary secretion. A basal secretion of saliva remains in all cases because of the presence of the minor 
salivary glands and due to the inefficacy of the toxin near the portion of the salivary glands with 
adrenergic innervations.  
This basal secretion was shown to be important because it protected the patients against oral cavity 
infections without causing or aggravating xerostomia or dry mouth caused by radiotherapy. 
The most important side effect related to the botulinum toxin injections is symptomatic xerostomia. 
This side effect must be indicated in the specific patient’s consent, because after radical surgery almost 
all patients are submitted to radiotherapy. On the 45th day after the toxin infiltration, all the patients 
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again underwent a quantitative measurement of salivary secretion which returned to a normal level in 
36 of the patients. No complications due to toxin infiltration were noticed. During the first week after 
surgery five patients had local complications, due to fungus infection, showing dehiscence of sutures 
(three patients) and oro-cervical fistula formation (two patients, 4.6%).  
3. Conclusions  
In this series the reduction of saliva secretion after botulinum toxin injections caused a reduction in 
the incidence of local saliva-related complications, improving wound healing, producing faster 
recovery, faster return to natural oral feeding and a shorter post-operative period. The effect of the 
drug is temporary and the risk of side effects is low. The technique of injections is easy and well 
tolerated by patients.  
In patients included in this study the percentage of complications related to salivary stagnation 
appears to be considerably reduced compared to other data in the literature. A precise valuation cannot 
be done because it is difficult to determine which complication can be attributed exclusively to the 
salivary stagnation and which not. Even though the study did not consider a control group, because of 
the small number of patients each year, it was possible to estimate and compare the post-operative 
complications in patients who had had a surgery in our department between the years 2000 and 2004. 
In fact during this period the botulinum toxin injections in major salivary glands were not carried out. 
There were only 12 patients who were operated on between 2000 and 2004 for oral cavity carcinoma 
with microsurgical reconstruction and presented similar characteristics to the group of 43 patients 
operated on between the years 2004 and 2012. In nine of twelve cases the flap used for reconstruction 
was the antebrachial free flap, in two cases ALT and only one case of fibular flap. There were six 
cases with local complications. In three cases a partial dehiscence of oral surgical suture appeared in 
the correspondence of the passage point of the vascular pedicle through the oral cavity floor, with 
formation of oro-cutaneous fistula which healed spontaneously. In another two cases the surgical 
suture dehiscence caused total detachment of the flap and oro-cervical fistula formation. In both cases 
another two minor operations were needed for revision of the sutures, debridement and closure of the 
fistula 15 and 30 days after surgery. In one case an infection in correspondence of the oral cavity floor 
under the chinese flap caused a thrombosis of the vascular pedicle with necrosis of the microsurgical 
flap frankly evident seven days after surgery. The removal of the flap was necessary and the 
reconstruction with pectoralis a major myocutaneopus flap was carried out. Reconstruction with a 
pectoralis major flap used to be more frequent previously, while these days it represents a rescue 
procedure, especially when another microsurgical intervention is controindicated. Even the pectoralis 
flap reconstruction is not free of complications related to salivary stagnation.  
This experience demonstrates that the toxin enables a reduction in local saliva-related 
complications, but it is difficult to determine the real rates of reduction of local complications in this 
series because of their multifactorial etiology. Statistical analysis of these data suggests that botulinum 
toxin in salivary glands is highly effective in reducing salivation and probably the related 
complications in the oral cavity (p < 0.001). The temporary inhibition of salivary secretion at the  
post-operative stage could enable a reduction in both saliva-related local complications and the 
incidence of oro-cutaneous fistulas. It could improve wound healing producing a faster recovery, a 
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faster return to natural oral feeding and a shorter postoperative period, thus improving the outcome of 
the surgery and ultimately the quality of residual life of these patients. 
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